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Abstract: A discrete acyl carrier protein (ACP) bearing a photolabile 
nonhydrolysable carba(dethia) malonyl pantetheine cofactor was 
chemoenzymatically prepared and utilized for the trapping of 
biosynthetic polyketide intermediates following light activation. From 
the in vitro assembly of the polyketides SEK4 and SEK4b by the type 
II actinorhodin ‘minimal’ polyketide synthase (PKS), a range of 
putative ACP-bound diketides, tetraketides, pentaketides and 
hexaketides were identified and characterised by FT-ICR-MS, 
providing direct insights on active site accessibility and substrate 
processing for this enzyme class.  
Polyketides constitute a prominent family of structurally and 
functionally diverse secondary metabolites, comprising renowned 
pharmaceuticals, agrochemicals and other products of 
commercial interest. [1] Their biosynthesis proceeds through 
multiple decarboxylative Claisen condensation steps, involving 
acyl carrier protein (ACP)-bound malonates and ketosynthase 
(KS) bound acyl units (Fig. 1 and 2A). A polyketide carbon 
backbone is assembled and modified, while remaining PKS-
bound, by auxiliary enzymes (ketoreductases, KRs; dehydratases, 
DHs; and enoylreductases, ERs), until it is eventually released 
from the PKS (typically by thioesterase (TE) mediated 
hydrolysis/cyclisation) and further enzymatically elaborated to the 
mature bioactive product. [2] PKSs are classified as ‘modular’ or 
‘iterative’ and into different types according to their structural 
organization and modus operandi. [3]  
Clinically important compounds such as the anticancer 
agents doxorubicin and daunorubicin are products of type II 
iterative polyketide synthase (iPKS) biocatalysis. [4] Iterative PKSs 
comprise single enzymes (type III), single multi-domain modules 
(type I), or discrete enzymes (type II) which repetitively employ 
the same catalytic activities to assemble and modify polyketide 
carbon chains. In comparison to modular PKSs, for which the 
nature of polyketide products is mostly predictable on the basis of 
module number and composition and can be altered or evolved, 
[5] the investigation and the re-programming of iPKSs remain 
challenging and underexploited.    
 
Figure 1. SEK4/SEK4b biosynthesis by the type II actinorhodin (act) ‘minimal 
system’: malonyl ACP decarboxylative Claisen condensation, driven and 
controlled by act KS-CLF (Fig.2A), generates an ACP-bound octaketide (2). In 
the absence of further enzymatic processing (e.g. by a KR domain), SEK4 and 
SEK4b (4 and 5) are the main products resulting from spontaneous octaketide 
cyclisation, dehydration and aromatisation. Legend: ACP= Acyl Carrier Protein; 
KS-CLF= Ketosynthase- Chain Length Factor; KR= ketoreductase.    
 
Within iPKSs, type II systems are distinctive biomolecular 
factories: they are found prevalently in Gram positive 
Actinomycetes [4] and are made of discrete proteins acting in a 
concerted manner to ultimately generate complex aromatic 
metabolites, including tetracyclines, anthracyclines, 
benzoisochromanequinones, tetracenomycins, aureolic acids, 
angucyclines and pentagular polyphenols. Type II PKSs closely 
resemble type II fatty acid synthases (FASs) in their essential 
mechanisms of substrate processing, however they differ in terms 
of intermediate nature and substrate binding modes adopted by 
their essential ACP components.[6]  Over time, the complex nature 
of protein-protein and protein-substrate interactions, as well as 
the fast kinetics of product assembly presented by these enzymes, 
have been the object of intense scrutiny.[7] For these studies 
model type II ‘minimal’ PKS systems have often been used. In this 
work, the actinorhodin minimal system has been our model 
system of choice.     
A type II ‘minimal’ PKS is constituted by a heterodimeric 
ketosynthase (KS) - chain length control (CLF) domain, [8] which 
catalyses and controls polyketide chain initiation and elongation; 
and by a discrete acyl carrier protein (ACP).  This ACP delivers 
malonyl building blocks and intermediates to the KS-CLF complex 
to construct a polyketone chain via the 4’-phosphopantetheine 
(PPant) cofactor (Figures 1 and 2A). [9] A malonyl Coenzyme A: 
ACP transacylase (MCAT) normally provides malonyl extender 
units to discrete type II ACPs, however this is not strictly required 
for a minimal system to function as type II ACPs can self-
malonylate. [10] In the absence of the ketoreductase actIII the 
postulated ACP-bound octaketide (2) spontaneously folds to 
afford shunt products: in the case of the aromatic antibiotic 
actinorhodin, these are the octaketides SEK4 and SEK4b (4 and 
5 respectively, Fig. 1). [8, 10] In the presence of the ketoreductase 
actIII the postulated ACP-bound octaketide (2) is converted to 
mutactin (3, Fig. 1), [11] whereas the combined action of actIII-act 
VII (act ketoreductases, aromatase, cyclase and oxidases)  
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Figure 2 (A) Devised type II PKS intermediate capture by the discrete acyl carrier protein ‘trap’ 8: this would compete with natural malonyl ACP 7 for polyketide 
chain extension, leading to accumulation of ACP-bound nonhydrolysable intermediates. (B) Chemoenzymatic preparation of photolabile carba(dethia) malonyl ACP 
9 which, upon irradiation at 365 nm, generates 8; (C) FT-ICR-MS absorption mode detection of a putative nonhydrolysable ACP-bound tetraketide 11 (13C-labelled, 
8+ charged state) in type II minimal act PKS assays containing both 8 and 13C3-malonyl ACP (SI), with the latter in excess; (D) FT-ICR-MS detection of a putative 
nonhydrolysable ACP-bound cyclised dehydrated hexaketide species 12 (7+ charged state) in similar assays containing both 8 and 7, with the former in excess (for 
further details, additional detected species and autocorrelation analyses please see the SI). 
 
ultimately convert 2 to actinorhodin (6). [12] For type II PKSs, 
malonyl-CoA remain the only elongating unit known to date, 
whereas a variety of acyl building blocks (e.g. acetate, propionate, 
(iso)butyrate, benzoate, …) can be used to prime these enzymes, 
and, together with post-PKS tailoring enzymes (e.g. cyclases, 
oxidases, aromatases and methyltransferases), contribute to the 
structural variation of type II PKS products. [4] In vitro 
reconstitution of enzyme activity [8, 10] and in vivo genetic 
manipulation [13] have proved crucial in gathering the first insights 
into the determinants of enzyme priming and chain length control. 
More recent biophysical studies (e.g. X-ray crystallography [14] 
and NMR [15]) of type II PKS proteins have provided more in-depth 
knowledge on protein-substrate recognition and productive 
conformations. Some of these investigations have relied on the 
enzymatic loading of synthetically prepared intermediate mimics 
of ACPs, as the natural ACP-bound intermediates are intrinsically 
unstable and highly reactive. [15, 16] The general inability of directly 
monitoring iterative intermediate formation and processing in real 
time constitutes a significant hurdle in gathering new knowledge 
of enzyme kinetics and protein-substrate interactions required to 
devise novel synthetic biology. [17] In our labs we have established 
a chemical ‘chain termination’ methodology aimed at the capture 
of transient polyketide biosynthetic intermediates in vitro [18] and in 
vivo. [19-20] The method is based on the use of small molecule 
probes that are nonhydrolysable mimics of ACP-bound malonate 
units. In competition with these last, the probes react with 
enzyme-bound biosynthetic intermediates to off-load them in a 
readily available and stable form for LC-MS characterisation. 
More recently we also reported the development of 
nonhydrolysable mimics of PCP (peptidyl carrier protein)-bound 
amino acids for the investigation of nonribosomal peptide 
assembly. [21] 
Herein we sought to extend the scope of our methodology 
to develop protein-based tools aimed at intermediate capture in a 
more stringent fashion. In particular, we envisaged that an acyl 
carrier protein, modified with a nonhydrolysable mimic of malonyl 
pantetheine, may act as an intermediate ‘trap’ for biosynthetic 
intermediates involved in type II PKS assembly, in competition 
with the natural malonyl ACP 7 (Fig. 2). In order to explore this 
and gather novel insights into the act type II PKS minimal system, 
a photoactivatable acyl carrier protein 9 was chemoenzymatically 
prepared according to Schemes 1S and 2S. The 4,5-dimethoxy-
2-nitrobenzyl (DMNB) photolabile group [22] was chosen as a 
means to protect the pseudo-malonate moiety of carba(dethia) 
malonyl ACP 8, due to its relative ease of synthetic incorporation 
and controllable removal at a non-protein damaging wavelength 
(365nm).  
From commercially available D-pantothenic acid the 
photolabile pantetheine derivative 10 was synthesised in 6 steps  
(Scheme 1S) and employed as substrate for the recombinant 
E.coli enzymes PanK, PPAT and DPCK, [23] to generate the 
corresponding coenzyme A photolabile derivative (Scheme 2S). 
Upon incubation of the latter with recombinant act apo-ACP and 
the phosphopantetheinyl transferase Sfp, [24] the desired 
photolabile ACP probe 9 was obtained (Fig. 2B). Light-activation 
of 9 was trialed in the absence and in the presence of the act KS-
CLF, employing either a KiloArc Broadband Arc Lamp or in an in-
house built light box containing a circular 22W UVA lamp [22]  (SI). 
While isolated 9 could be deprotected to 8 within a 4 hour 
irradiation period (Fig. 2S), negligible deprotection of 9 took place 
in the presence of the act KS-CLF (Fig.  3S). Enzymatic assays 
for the production of SEK4 and SEK4b by hexahistidine-tagged 
act ACP and KS-CLF were set up as previously reported, [10, 25] 
adding the pre-photolysed and untagged ACP 8 at different times 





and variable concentrations (Table 1S). Enzymatic assay filtration 
through Ni-NTA agarose beads was carried out in order to 
selectively isolate any species deriving from the ‘unnatural’ ACP 
8. The samples recovered from this operation were concentrated 
and buffer-exchanged ahead of direct infusion into an FT-ICR-MS 
spectrometer (SI). The outcome of these experiments is 
illustrated in Fig. 2 and detailed in the Supplementary Information 
(SI, Table 1S).  
In selected samples, putative ACP-bound nonhydrolysable 
intermediates, including di, tetra, penta and hexaketide species 
(including mono- and di-dehydro species) were identified and 
characterised by HR-MS analysis of protein-charged states 
ranging from 11+ to 6+; these species were absent in control 
samples  (SI). Also, in assays of KS-CLF with 13C3-malonyl ACP 
(instead of 7) and 8, putative ACP-bound nonhydrolysable 
species bearing an even number of 13C atoms were observed (Fig. 
2(C) and SI), consistent with their expected polyketide nature. 
Overall, in the analyses of KS-CLF assays in the presence of 8, 
carba(dethia) acetyl-ACP was the most abundant species, 
whereas the putative captured intermediates were present in low 
abundance. To characterise further these species without 
additional sample manipulation, the 4’-phosphopantetheine 
(PPant) ejection assay [26] was attempted directly on the 
heterogeneous samples infused into the FT-ICR-MS, however 
this did not lead to small molecule detection. The 4’-PPant 
ejection assay employs collisionally activated dissociation (CAD) 
to preferentially cleave the 4’PPant ion. However, we cannot 
exclude CAD possibly fragmenting the enzyme-bound polyketide 
species in the conditions employed to analyse such complex 
mixtures. In order to improve the confidence with which we 
identified low abundance putative ACP-bound species, we used 
autocorrelation to identify periodic patterns in data. The result of 
the isotopic distribution of the ion at the right charge state can 
indeed support the identification of signals close to the noise 
threshold, as demonstrated by Palmblad et al. [27] The results of 
this approach applied to our samples supported the assignment 
of the manually identified putative species (see SI).  
Amongst the identified species, ACP-bound diketide and 
tetraketide species were most abundantly detected in samples 
deriving from the simultaneous addition of 8 and 7 (or its 13C3-
labelled version), whereas a putative di-dehydro hexaketide (Fig. 
9S) was the most commonly observed product, in a variety of 
conditions (Table 1S). Parallel experiments, conducted using 
photolabile N-acetylcysteamine-based chain termination probes 
[22] in the in vitro assembly of SEK4 and SEK4b, did not lead to 
any off-loaded putative intermediates (data not shown), leading 
us to postulate that the ACP probe interacts more efficiently with 
the minimal system. 
The assembly of actinorhodin by the act PKS, as well as that 
of related products and other type II PKS-derived metabolites, has 
been the object of intensive scrutiny and still holds a number of 
unresolved questions, including several concerning intermediate 
sequestration and stabilisation and protein-protein interactions.[15]  
Herein we have shown that, through the use of a 
chemoenzymatically generated malonyl ACP nonhydrolysable 
mimic (8), direct evidence of novel ACP-bound polyketone 
species involved in type II PKS assembly can be obtained. These 
species, in contrast to others previously reported, [28] are 
nonhydrolysable from the carrier protein, hence they should 
constitute useful chemical biology tools for mechanistic and 
structural investigations.  
The ability of 8 to intercept putative biosynthetic 
intermediates in vitro, such as those herein presented, and, 
conversely, the inability of N-acetylcysteamine based probes to 
do so (data not shown), support that, for the type II act minimal 
system, the KS-CLF active site is mostly accessible to ACP-
bound substrates rather than free species. The varied nature of 
putative ACP-bound intermediates observed in our experiments, 
including in those where the unnatural pseudo-malonyl ACP 8 
was present in defect to the natural malonyl ACP substrate 7, 
suggests dynamic interactions between the KS-CLF and the ACP, 
with proteins that can interchange, [29] and protein-protein 
interactions efficiently guiding ACP-bound substrates into the KS 
active site for processing. [30] The putative captured ACP-bound 
species detected in these experiments may possibly reflect the 
kinetics of carbon chain assembly and folding, with specific steps, 
e.g. diketide and tetraketide formation, relatively slow in 
comparison to others. This would be in agreement with 
crystallographic studies of act KS-CLF ‘caught in action’ with a 
diketide and a tetraketide species bound to its cysteine active site. 
[14] Further work will be required to corroborate the preliminary 
insights gathered by our experiments. Nonetheless, the ACP 
probe 8 herein prepared and evaluated constitutes a rare example 
of protein ‘trap’ for biosynthetic species [31] and the first for 
polyketide synthases. Its use in conjunction with advanced FT-
ICR-MS analyses and data analysis tools represents a new 
promising approach for the study of challenging biosynthetic 
enzymes that make use of dynamic carrier proteins, including fatty 
acid synthases and nonribosomal peptide synthetases.  
Experimental Section 
The chemoenzymatic preparation of 9,  its photolysis to 8 and use 
of 8 in enzymatic assays generating SEK4 and SEK4b, as well as 
FT-ICR-MS analyses of putative captured enzyme-bound 
intermediates, are reported in the Supplementary Information. 
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